Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM ...

Exl-111 is an investigational allergic Effector Cell Response Inhibitor (ECRI) targeting the IgE axis and is designed to disarm allergic ...
Seeking Alpha

eFFECTOR soars as Stifel upgrades after Phase 2 data for cancer drug combo

eFFECTOR Therapeutics (NASDAQ:EFTR) jumped ~117% in the pre-market Friday after Stifel upgraded the nano-cap biotech citing interim Phase 2 data for the company's investigational therapy zotatifin as ...
Seeking Alpha

EFTR eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate ...
News Medical

Fc-effector functions for selecting COVID-19 convalescent plasma

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that coronavirus disease 2019 (COVID-19) convalescent plasmas (CCPs) with low neutralizing and high fragment ...